Abstract:Engineering immune cells to express chimeric antigen receptors (CARs) allows the recognition of specific tumor-associated antigens, enhancing the immune cells' potential for identification and elimination of tumor cells. In glioblastoma (GBM), the most common and aggressive primary central nervous system (CNS) tumor in adults, standard treatment—which includes maximal surgical resection followed by cycles of chemotherapy and radiotherapy—often leads to recurrence, with an average survival of about 15 months. This happens partly due to the presence of glioblastoma stem cells (GSCs), which are resistant to conventional treatments and possess tumor-initiating properties, highlighting the need for targeted therapies. CAR technology has been applied to various cell types, but Natural Killer (NK) cells, in particular, offer unique advantages, such as feasibility for allogeneic transplants and reduced cytotoxicity risks. Preclinical and some clinical studies have shown that CAR-NK cells can efficiently eliminate target cells with minimal side effects, though few studies have focused on GBM. Given the need for improvement in GBM therapy, we developed a third-generation CAR receptor adapted for expression in NK cells, incorporating two antigen-binding domains specific to selected GSC markers associated with GSC maintenance and tumorigenic potential. We evaluated the cytotoxic potential of CAR-NK cells vs. Mock-NK cells (control) against GBM cell lines through co-culture assays. After in silico analysis for relevant GSC markers, we verified antigen expression in GBM cell lines (A172, LN18, U87-MG, U138-MG, U251-MG, U343-MG) by flow cytometry (FC) and immunocytochemistry (ICC), in both tumor cell monolayer and tumor spheres. CAR-NK cells were produced by transducing NK-92 cells with a lentiviral vector carrying the CAR construct. Efficiency was confirmed via FC, neomycin selection, and RT-qPCR. CAR-NK and Mock-NK cells were co-cultured with ZsGreen+ U251-MG cells, and cytotoxicity was assessed using LDH release assays and fluorescence microscopy (FM). Results showed that the selected antigens were expressed in all six GBM cell lines, with increased expression in tumor spheres indicating their relevance as GSC markers. CAR-NK cells demonstrated superior cytotoxicity compared to Mock-NK cells, as indicated by higher death rates in LDH assays and greater fluorescence reduction detected by FM after co-cultivation with ZsGreen+ U251-MG. In conclusion, the selected GSC antigens are promising targets for designing CARs against GBM cells. The CAR-NK cells exhibited superior cytotoxic activity compared to Mock-NK cells, suggesting effective targeting of GBM cells. Further in vivo experiments are underway to confirm these findings and evaluate CAR-NK cell activity for potential clinical applications. Citation Format: Vitoria A Lima, Thiago G Mitsugi, Oswaldo K Okamoto. Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B034.

Studies on Cytotoxicity of Natural Killer (NK) Cells against Glioma Initiating Cells in Vitro

Role of HLA-G and NCR in Protection of Umbilical Cord Blood Haematopoietic Stem Cells from NK Cell Mediated Cytotoxicity.

Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro

The effects of NK cells and drug combination therapy on glioblastoma tumor growth

Study of Multi-Directional Derivation of Cord Blood Mononuclear Cells and Observation of Killing Activity to MGC-803 Gastric Cancer Cell Strain in Vitro

Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis

Effect of Killer Cell Induced by Cytokines on the Killing Activity to GBC-SD Gallbladder Cancer Cell Strain

Immu-69. Therapeutic Window Enabling Eradication Of Residual Glioma Stem Cells By Intracranial Nk Cell Therapy Following Temozolomide-Induced Tumour Depopulation – A Possible Role Of Cytotoxic Extracellular Vesicles

Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells

Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model

Intra-lesion injection of activated Natural Killer (NK) cells in recurrent malignant brain tumors

Cytotoxicity of activated natural killer cells against pediatric solid tumors

GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo

Activation of Glioma Cells Generates Immune Tolerant NKT Cells.

Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity

[Efficacy and peripheral immunity analysis of allogeneic natural killer cells therapy in patients with hepatocellular carcinoma]

Proliferation of human natural killer cells induced with irradiated allogeneic peripheral blood mononuclear cells ex vivo

Copy Number Variations of HLA-I and Activation of NKp30 Pathway Determine the Sensitivity of Gastric Cancer Cells to the Cytotoxicity of Natural Killer Cells

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

Abstract B034: Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors